N-(indolcarbonyl-)piperazine derivatives
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 4, 2005
Grant Date -
N/A
app pub date -
Jun 3, 2002
filing date -
Jul 22, 1999
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.4 and R.sup.5 have the meanings indicated in claim 1, are potent 5-HT.sub.2A antagonists and are suitable for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkingson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia, nervous anorexia, premenstrual syndrome and/or for positively affecting compulsive behavior (obsessive-compulsive disorder, OCD).
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully